SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Koninklijke DSM N.V. (RDSMY) trades at a trailing P/E of 31.1. Trailing earnings yield is 3.22%. PEG 0.63 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (60/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.63).
- PEG Ratio 0.63 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 3.22% — roughly competitive with bond yields (~4.3%), moderate risk-reward.
Overall SharesGrow Score: 68/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — RDSMY
Valuation Multiples
P/E (TTM)31.1
Forward P/EN/A
PEG Ratio0.63
Forward PEGN/A
P/B Ratio0.00
P/S Ratio2.52
EV/EBITDA0.0
Per Share Data
EPS (TTM)$1.09
Book Value / Share$0.00
Revenue / Share$13.41
FCF / Share$0.00
Yields & Fair Value
Earnings Yield3.22%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2012 |
$0.43 |
$9.13B |
$288M |
3.2% |
| 2013 |
$0.39 |
$9.05B |
$271M |
3% |
| 2014 |
$0.21 |
$9.18B |
$145M |
1.6% |
| 2015 |
$0.13 |
$7.72B |
$88M |
1.1% |
| 2016 |
$0.88 |
$7.92B |
$621M |
7.8% |
| 2017 |
$2.52 |
$8.63B |
$1.77B |
20.5% |
| 2018 |
$1.53 |
$9.27B |
$1.08B |
11.6% |
| 2019 |
$1.07 |
$9.01B |
$758M |
8.4% |
| 2020 |
$0.73 |
$8.11B |
$506M |
6.2% |
| 2021 |
$1.09 |
$9.2B |
$747M |
8.1% |
